CareDx Strengthens Bioinformatics Capabilities with Acquisition of BFS Molecular

Published: Mar 17, 2021
SOUTH SAN FRANCISCO, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc.. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired BFS Molecular S.R.L., a software company focused on NGS-based patient testing solutions.
BFS Molecular brings extensive software and algorithm development capabilities for NGS transplant surveillance products that will add value to CareDx’s portfolio, including AlloSeq cfDNA and AlloSeq HCT. In addition to the acquisition of BFS Molecular, Tim Hague, CEO and Co-Founder of BFS Molecular, will join CareDx as Vice President of Global Lab Products Software. Mr. Hague was previously CEO of Omixon, a highly regarded innovator of NGS HLA typing solutions.

Related Keywords

California , United States , South San Francisco , Sasha King , Greg Chodaczek , Tim Hague , Global Lab Products Software , Caredx Inc , Nasdaq , Vice President , Global Lab Products , Greg Seeto , Annual Report , Resume , Careers , Caredx Strengthens Bioinformatics Capabilities With Acquisition Of Bfs Molecular , Biospace , Advice , கலிஃபோர்னியா , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு சான் பிரான்சிஸ்கோ , சாஷா கிங் , நேரம் ஹேக் , உலகளாவிய ஆய்வகம் ப்ராடக்ட்ஸ் மென்பொருள் , நாஸ்டாக் , துணை ப்ரெஸிடெஂட் , உலகளாவிய ஆய்வகம் ப்ராடக்ட்ஸ் , ஆண்டு அறிக்கை , தற்குறிப்பு , தொழில் ,